Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia

Infectious Diseases in Clinical Practice

Volumn 21, Issue 1, 2013, Pages 58-60

  Zainah, Hadeel ^a   Vazquez, Jose A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

bacteremia; ceftaroline; MRSA

Indexed keywords

CEFTAROLINE; CREATININE; DAPTOMYCIN; GENTAMICIN; HEMOGLOBIN; LINEZOLID; METRONIDAZOLE; RIFAMPICIN; VANCOMYCIN;

ADD ON THERAPY; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; CASE REPORT; CREATININE BLOOD LEVEL; FEMALE; FEVER; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; SEPTIC SHOCK; STAPHYLOCOCCUS EPIDERMIDIS; THROMBOCYTE COUNT;

EID: 84872062378     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e3182602205     Document Type: Article

References (13)

1. Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother. 2012;56(2):634-638.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious disease society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.
3. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66(suppl 3):iii11-iii18.
4. Girish C, Balakrishnan S. Ceftaroline fosamil: a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin. J Pharmacol Pharmacother. 2011;2(3):209-211.
5. Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49(8):3501-3512.
6. Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54(7):3027-3030.
7. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blind, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl 3):iii19-iii32.
8. Low DE, File TM Jr, Eckburg PB, et al. On behalf of the FOCUS 2 investigators. FOCUS 2: a randomized, double-blind, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl 3):iii33-iii44.
9. Corey RG,Wilcox MH, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl 4):iv41-iv51.
10. Wilcox MH, Corey RG, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl 4): iv53-iv65.
11. Talbot GH, Thye D, Das A, et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2007;51(910):3612-3616.
12. Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother. 2007;51(9): 3397-3400.
13. Jacqueline C, Amador G, Batard E, et al. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother. 2011;66:863-866.